Cigna has reported that the percentage of employers covering obesity drugs has remained flat year-over-year, despite the health insurer observing an uptick in demand for these popular treatments. This trend suggests a potential disconnect between patient and physician interest and employer willingness to fund coverage.
The flat coverage rate, even with rising demand, indicates that employers may be grappling with the high costs associated with GLP-1 weight-loss medications. This could lead to continued scrutiny of pricing and the development of more value-based management strategies for these drugs.
This market insight from Cigna highlights the ongoing challenges in expanding access to weight-loss drugs, despite their clinical effectiveness. It suggests that cost-management solutions, such as Cigna's recently announced $200 cap on out-of-pocket costs for Wegovy and Zepbound, will be crucial for broader adoption.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.